Topics:

Humanized Anti-CCR5 MoAb Blocks HIV Entry: Preclinical Trial

Humanized Anti-CCR5 MoAb Blocks HIV Entry: Preclinical Trial

SAN DIEGO, California—Pro-genics Pharmaceuticals’ humanized monoclonal antibody (MoAb) PRO 140 has been shown to block HIV entry into immune system cells. The agent acts by binding to a portion of the CCR5 fusion coreceptor present on the outer membrane of immune system cells. William C. Olson, PhD, vice president of research and development at Progenics, Tarry-town, New York, presented the research at the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (abstract H-178).

The agent’s antiviral activity was examined using both whole-virus p24 assays and a novel fluorometric fusion assay. The virologic studies examined a broad range of wild-type and drug-resistant HIV-1 isolates and diverse primary target cell types.

The researchers found that PRO 140 actively blocked HIV-1 replication in target cells as diverse as T cells, macrophages, and dendritic cells. The agent was similarly effective in blocking infection of T cells by dendritic-cell-associated virus in trans. Viral replication was completely suppressed at PRO 140 levels that had little or no effect on CC-chemokine signaling through CCR5 and other normal immunologic activities.

The researchers also showed that PRO 140 is synergistic in combination with other investigational HIV-1 entry inhibitors, including Progenics’ PRO 542, which blocks the CD4 coreceptor by binding to gp 120, and Roche/Trimeris’ fusion inhibitor enfuvirtide (Fuzeon, T-20), which works by blocking the gp 41 protein. [See ONI October 2002, page 13, for a report on enfuvirtide.]

The parent mouse antibody was recently humanized to support repeated dosing in humans, and humanized PRO 140 is entering phase I clinical testing. "Humanized PRO 140 broadly and potently blocks HIV-1 entry through CCR5 without interfering with the receptor’s normal activity and should be advanced into human clinical testing," Dr. Olson concluded. 

 
Loading comments...
Please Wait 20 seconds or click here to close